相关临床试验
0
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Aarvik Therapeutics successfully closed its Series Seed 2 financing round with investments from multiple investors including Laurus Labs, validating progress on its proprietary MUTTA™ platform. - The company's MUTTA™ platform focuses on developing next-generation antibody drug conjugates that can expand ADC success beyond limited targets by improving therapeutic windows. - Funding will enable Aarvik to reach targeted research milestones and further advance its pipeline of ADC assets for hard-to-treat cancer indications.
- Gilead Sciences filed a patent infringement lawsuit against Laurus Labs in 2018 over generic versions of tenofovir disoproxil fumarate (TDF), a cornerstone HIV and hepatitis B treatment. - The Patent Trial and Appeal Board invalidated certain claims in Gilead's patent during inter partes review proceedings, weakening the company's enforcement position. - The companies reached a settlement in 2020 that included licensing agreements and allowed Laurus to market generic versions under specified conditions. - The case demonstrates the strategic importance of inter partes review proceedings in challenging pharmaceutical patents and facilitating generic drug market entry.
- ImmunoACT reported ₹62 crore in revenue and ₹12 crore profit before tax in FY25, marking rare profitability for an Indian biotech startup in its first full year of operations. - The company's NexCAR19 therapy, priced 90% lower than US and European counterparts, has been administered to over 350 patients across 70 hospitals since its April 2024 launch. - NexCAR19 demonstrated significant clinical benefits with 40% progression-free survival in B-cell non-Hodgkin lymphoma and 60% in B-cell acute lymphoblastic leukemia patients. - The therapy's cost has decreased from ₹42 lakh to ₹30 lakh per dose, with further price reductions expected as production scales and demand increases.
- Indian Contract Research and Development and Manufacturing Organizations (CRDMOs) are attracting increased attention from global pharmaceutical companies as Big Pharma pursues geographic diversification strategies. - Rising demand for antibody-drug conjugate (ADC)-related CDMO services and future opportunities in GLP-1 diabetes and obesity treatments are positioned as significant growth drivers from 2026. - Key players including Piramal Pharma, Syngene, Laurus Labs, Cohance, and Gland Pharma are strategically positioning for future gains despite current destocking challenges affecting near-term growth. - Gland Pharma is expanding its GLP-1 cartridge fill-finish capacity from 40 million to 140 million units by the end of next year, reflecting the industry's optimistic long-term outlook.
